Lemborexant for Cannabis Use Disorder

The goal of this clinical trial is to investigate the use of Lemborexant as a treatmentfor moderate to severe Cannabis Use Disorder (CUD). The main questions it aims to answerare: 1. Is Lemborexant safe, feasible, and tolerable to use in the CUD population? 2. Will the use of Lemborexant for CUD help to decrease cannabis use, improve sleep,decrease cannabis withdrawal symptoms, and improve cognition?Researchers will compare 10mg Lemborexant to placebo.Participants will: ‐ Take 10mg Lemborexant (or placebo) nightly for 21 nights (treatment phase). ‐ Wear an actigraphy watch continuously for the treatment phase. ‐ Complete a pre‐screen survey, attend an in‐person screening session, 4 in‐person labvisits (weekly from days 0‐21), and a virtual follow‐up visit 2 weeks after thetreatment phase. ‐ Complete a short daily survey for 35 days total.